Studies evaluate levothyroxine’s impact on cardiovascular disease risk in midlife and older women and in adults with ...

Zydus Lifesciences announced that it has received approval from Health Canada to market Liothyronine tablets, a therapeutic ...

Zydus Lifesciences announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Liothyronine tablets in 5 mcg and 25 mcg strengths.

Zydus Lifesciences received regulatory approvals from Health Canada for generic Liothyronine tablets and from the USFDA for ...

Hypothyroidism was associated with an increased risk for small intestinal bacterial overgrowth across sexes, age groups, and BMI categories.

A new study from Boston University has found that surgery may be a better long-term treatment for people with hyperthyroidism ...

SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after ...

A recent announcement by the Food and Drug Administration about natural thyroid treatment has readers of this newspaper column up in arms. Nearly 5 percent of American adults have a thyroid gland that ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

We break down why "just a shampoo" is never the answer for dog hair loss and what the real path to a healthy coat involves ...

Most patients with low-risk differentiated thyroid cancer do not require levothyroxine therapy at 3 years after hemithyroidectomy.